[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

+86-021-51370693

Email address

hybao@maxinovel.com

Condition

Metastatic Colorectal Cancer,Pretreated Local Advanced or Metastatic Colorectal Cancer

Treatment type

Interventional

Investigational product

MAX-40279-01

Phase

Phase 2

Sponsor

Maxinovel Pty., Ltd.

ClinicalTrials.gov identifier

NCT05130021

Study number

MAX-40279-005

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

This include two parts, part 1 is a dose optimizing study and part 2 is a randomized, controlled study.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

  1. Males and/or females over age 18
  2. Histologically and/or cytologically documented local advanced or metastatic colorectal adenocarcinoma.
  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  4. Expected survival >3 months.
  5. previously treated with standard, approved therapies, including two lines of chemotherapy (fluoropyrimidine,oxaliplatin and irinotecan based), a biological VEGF inhibitor, and, if RAS wild-type, an EGFR inhibitor. Patients with MSI-H/MMR-deficient tumors also must have received an immune checkpoint inhibitor, if available and approved. In addition, patients with BRAF mutant tumors must also have received a BRAF inhibitor, if available and approved.
  6. Signed informed consent form.
Exclusion criteria

  1. Known uncontrolled or symptomatic central nervous system metastatic disease.
  2. Adverse events (with exception of alopecia, peripheral sensory neuropathy grade ≤ 2 and those listed in specific exclusion criteria) from any prior anticancer therapy of grade >1 (National Cancer Institute Common terminology Criteria [NCI CTCAE] v.3.0) at the time of randomization.
  3. Inadequate organ or bone marrow function.
  4. Medical history of difficulty swallowing, malabsorption or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the tested product.
  5. Pregnant or breast-feeding woman.
  6. Known allergies, hypersensitivity, or intolerance to Max-40279-01 the excipients of these treatments The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site